Teva与Prestige合作,在大多数欧洲国家销售与生物类似的癌症药物Tuznue。 Teva partners with Prestige to sell biosimilar cancer drug Tuznue in most European countries.

Teva制药公司与Prestige生物制药公司签订了许可证和供应协议,以便在大多数欧洲市场上将Tuznue商业化,这是与Herceptin相似的生物产品。 Teva Pharmaceutical has secured a license and supply agreement with Prestige Biopharma to commercialize Tuznue®, a biosimilar to Herceptin®, in most European markets. 欧洲联盟委员会于2024年9月批准Tuznue 治疗HER2-呈阳性的乳腺癌和胃癌。 Approved by the European Commission in September 2024, Tuznue® treats HER2-positive breast and gastric cancers. Teva将利用其欧洲网络处理销售和分销,而Prestige则通过其经欧盟-GMP认证的设施来管理生产。 Teva will handle marketing and distribution using its European network, while Prestige manages production through its EU-GMP-certified facilities. 合作的目的是在整个欧洲扩大患者获得负担得起的、高质量的生物类同治疗的机会。 The collaboration aims to expand patient access to affordable, high-quality biosimilar treatments across Europe.